Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $47,275.47 in Stock

Dyadic International Inc. (NASDAQ:DYAIGet Free Report) major shareholder Francisco Trust Under Agreemen sold 25,281 shares of Dyadic International stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $1.87, for a total transaction of $47,275.47. Following the completion of the sale, the insider owned 3,496,907 shares in the company, valued at approximately $6,539,216.09. This trade represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Down 6.0%

DYAI opened at $1.00 on Thursday. Dyadic International Inc. has a twelve month low of $0.65 and a twelve month high of $1.35. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a 50-day moving average price of $0.78 and a 200 day moving average price of $0.83. The company has a market cap of $36.33 million, a PE ratio of -4.33 and a beta of 1.15.

Dyadic International (NASDAQ:DYAIGet Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Sell-side analysts expect that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

View Our Latest Research Report on DYAI

Institutional Investors Weigh In On Dyadic International

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Apis Capital Advisors LLC purchased a new position in shares of Dyadic International during the 3rd quarter worth $1,817,000. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International in the 3rd quarter valued at approximately $190,000. Marathon Capital Management raised its holdings in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the period. Geode Capital Management LLC increased its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

About Dyadic International

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.

Featured Stories

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.